DNA methylation analysis in liquid-based cytology for cervical cancer screening
โ Scribed by Sophia Apostolidou; Richard Hadwin; Matthew Burnell; Allison Jones; Donna Baff; Nitisha Pyndiah; Tim Mould; Ian J. Jacobs; Simon Beddows; Gabrijela Kocjan; Martin Widschwendter
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- French
- Weight
- 149 KB
- Volume
- 125
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Cervical cancer is the second most common type of cancer in women worldwide. Preinvasive disease can be detected by cervical cytology. All currently available cytology technologies rely on the visual analysis of exfoliated cells from the uterine cervix. Improvement of conventional cytological screening has been proposed by the introduction of molecularโbased markers applied to liquidโbased cytology (LBC), the suspension of cells collected from the cervix. DNA methylation changes occur very early in carcinogenesis and identification of appropriate DNA methylation markers in such samples should be able to distinguish highโgrade squamous intraepithelial lesions (HSIL) from nonspecific cytology changes and the normal cervix. To address this potential, we have undertaken a proofโofโprinciple study of methylation status of LBC samples from HSIL cytology cases compared against matched normal controls. Using quantitative methylationโspecific PCR on 28 genes, we found SOX1, HOXA11 and CADM1 to significantly discriminate between the groups analyzed (p < 0.01). Area under the receiver operating characteristic (ROC) curve (AUC) demonstrated that methylation of SOX1, HOXA11 and CADM1 could discriminate between HSIL cases and controls with high sensitivity and specificity (AUC 0.910, 0.844 and 0.760, respectively). The results were further validated in an independent set. This proofโofโprinciple study is the first to validate the results in an independent case/control set and presents HOXA11, a gene that is important for cervical development, as a potentially useful DNA marker in LBC samples. Further assessment of these preliminary estimates will need to be performed in a larger cohort to confirm clinical utility. ยฉ 2009 UICC
๐ SIMILAR VOLUMES
Supported by the U.S. National Cancer Institute through a series of contracts to the field staff's organization affiliated with the Costa Rican government, and with other contractors supporting the specimen handling and data management efforts. Some labor and supplies were supplied to the project at
## Background: Cervical carcinoma is a common malignancy among women worldwide, and its pathogenesis is related causally to human papillomavirus infection. the progression from precursor squamous intraepithelial lesions to cervical carcinoma requires additional genetic and epigenetic alterations th
The APTIMA V R HPV Assay (AHPV) allows detection of 14 high-risk human papillomavirus (HPV) RNA types in cervical specimens. Until present, the assay has been compared to HPV DNA tests only in triage settings. Herein, we compare AHPV with a DNA assay (Hybrid Capture V R 2; HC2) and liquid-based cyto
## Abstract Cervical cancer is an important public health problem in many developing countries, where cytology screening has been ineffective. We compared four tests to identify the most appropriate for screening in countries with limited resources. Nineteen midwives screened 5,435 women with visua